Mr. Venkateswar Rao is our chief financial officer. Mr. Rao is a great academician who had done B.Tech from Kakinada, India, MBA from
Naynang Technological University Singapore, CFO course from
Columbia University, New York. He had done other courses like Core
program (Business Analytics, Economics for Managers and Financial
Management) from Harvard Business school USA, Innovating digital
World- London Business School, Leadership and change management
from XLRI Jamshedpur.
He worked as a Banker for 23 Years (State Bank of India and HDFC
Bank Limited)
Worked as Group CFO and Group Managing Director of A Star Testing
and Inspection (S) Pvt Ltd Singapore.
With all this great expertise he is going to shape Arde’s Laboratories at par with the existing world of pharmaceuticals.
At Arde’s, Mr.Rao is responsible for the Company’s capital structure,
financial reporting, and stewardship of Company assets as well as
providing guidance on strategic decisions and business partnerships.
Brings a proven track record globally with more than 2 decades of experience in development, operations and business scaling with strong foundation in banking and implementing systems in start-ups and engineering companies. Knowledge in ensuring appropriate
organizational policies and participating in development of mission and strategic plan for companies and organizations.
Lanka Rao Konda formed Arde’s Laboratories with a 2-decade career in pharmaceutical industry. Started his carrier with Aurobindo Pharma, worked for Matrix Labs, Jubilant Life sciences, Actavis, Micro Labs and most recently NATCO Pharma.
He is a skilled leader worked in complex organizations, implementing high profile initiatives under tight frames on budget. He brings a strong understanding on the needs and operations of the company.
With broad range of pharmaceutical experience, he is responsible for the overall strategy, direction, and growth of the business.
He has extensive experience across a range of therapeutic areas, including oncology, metabolic diseases, inflammation, neurological
disease and cardiovascular disease. This have resulted in a broad range of successful achievements in getting marketing approvals for generic medicines.
